Interest in BiVictriX Therapeutics PLC's (AIM:BVX, OTC:BVTXF) product and platform are 'high', said broker Panmure Gordon in a note covering preclinical safety data from the company's lead asset.
BVX001, a next-generation treatment called an antibody drug conjugate (ADC), is designed to target acute myeloid leukaemia (AML) more precisely and effectively than the current standard of care while reducing harmful side effects.
In tests, it showed no severe eye damage at low to moderate doses and only minimal effects at higher doses. Overall, there were no severe tissue changes across all tested doses, with noticeable effects only at the highest dose levels.
Indeed, the toxicological profile of BVX001 compared favourably to other FDA-approved ADCs with similar drug payloads
This promising safety data makes BVX001 a strong candidate for further development, guiding how much of the drug can be safely given to patients. The data will be presented at the American Society of Hematology meeting in December.
However, the next stage is to take the drug candidate into the clinic, which is a costly endeavour. This means the group will in all certainly look for a fresh investment before taking the next step.
"Interest in the product and platform from potential partners and investors to date is significant, and management focus is on identifying the best source of funding," Panmure said in a note to clients.
"We see several options including industry partnership, product-specific funding, private investment or out-licensing."
Panmure is a 'buyer' up to 66p. In afternoon trading the shares were flat at 11.9p.